Anticancer effect of 1,2-epoxy-3(3-(3,4-dimethoxyphenyl)-4H-1-benzopiran-4on) Propane (EPI) and combination with Doxorubicin on HTB183 lung cell cancer culture
Ade Gafar Abdullah, Isma Widiaty, Cep Ubad Abdullah in Medical Technology and Environmental Health, 2020
Doxorubicin is a broad-spectrum anticancer drug that can be used in lung cancer therapy (Johnson-Arbor & Dubey 2017). There are two mechanisms of the doxorubicin process working against cancer cells; namely, doxorubicin can enter the cell nucleus and damage topoisomerase-II, then cause damage to the DNA and cell death. In addition, there are other mechanisms; in particular, doxorubicin is oxidized to semiquinone, an unstable metabolite, which is converted back into doxorubicin in the process of releasing reactive oxygen species. Reactive oxygen species can cause lipid peroxidation and membrane damage, DNA damage, and oxidative stress, and can trigger apoptotic pathways for cell death. Doxorubicin triggers cell death through activation of p53. The role of p53 apoptosis might be in its ability to disrupt the balance between antiapoptotic proteins (such as Bcl-XL, Bcl-2, and Mcl-1) and pro-apoptotic proteins (such as Bax and Bak) (Rathos et al. 2013).
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Malignancies
II-Jin Kim in Cancer Genetics and Genomics for Personalized Medicine, 2017
Doxorubicin, also hydroxyldaunorubicin, is a DNA-interacting drug widely used in chemotherapy. It is an anthracycline antibiotic which is structurally similar to daunomycin, both of which intercalate DNA. Doxorubicin is used in the treatment of a wide range of cancers and is administered by injection. The exact mechanism of action of doxorubicin is complex and still somewhat unclear, though it is understood to interact with DNA by intercalation, thereby inhibiting macromolecular biosynthesis. The planar aromatic chromophore portion of the doxorubicin molecule intercalates between two base pairs of DNA, while six-membered daunosamine sugar sits in the minor groove and interacts with flanking base pairs immediately adjacent to the intercalation site, as evidenced by crystallography.
Applications of Liposomal Drug Delivery Systems to Cancer Therapy
Mansoor M. Amiji in Nanotechnology for Cancer Therapy, 2006
The anthracycline antibiotic doxorubicin has a broad spectrum of antineoplastic action and a correspondingly widespread degree of clinical use. In addition to its role in the treatment of breast cancer, doxorubicin is indicated in the treatment of various cancers of the lymphatic and hematopoyetic systems, gastric carcinoma, small-cell cancer of the lung, soft tissue, and bone sarcomas as well as cancer of the uterus, ovary, bladder, and thyroid. Unfortunately, toxicity often limits the therapeutic activity of doxorubicin and may preclude adequate dosing. Other common complications of conventional anthracycline therapy include alopecia and dose-limiting myelosuppression. Most importantly, cardiotoxicity limits the cumulative dose of conventional anthracycline that can be given safely.42
Trastuzumab modified silica nanoparticles loaded with doxorubicin for targeted and synergic therapy of breast cancer
Published in Artificial Cells, Nanomedicine, and Biotechnology, 2018
Ling-xin Meng, Qiang Ren, Qin Meng, Yu-xiu Zheng, Mao-lei He, Shu-yan Sun, Zhao-jun Ding, Bing-cheng Li, Hui-yun Wang
Compared with monotherapy, combination chemotherapy for cancer therapy is considered as an important protocol for enhanced therapeutic effects and reduced systemic toxicity by simultaneously modulating multiple cell-signaling pathways. [18, 19] Doxorubicin (DOX) is a chemotherapy medication used to treat various kinds of cancers, including breast cancer. By intercalation and inhibition of macromolecular biosynthesis via interaction with intracellular DNAs, DOX can quickly exerted strong cytotoxicity effect on rapidly divided breast cancer cells. [20] DOX is often used together with other chemotherapy agents to further improve the anti-cancer performance as well as reducing the side effects. [21, 22] Here in this study, we try to explore whether combination of Tra and DOX can enhance the efficacy in breast cancer therapy via synergetic effects.
The Adjuvant Effect of Squalene, an Active Ingredient of Functional Foods, on Doxorubicin-Treated Allograft Mice
Published in Nutrition and Cancer, 2019
Hari Narayan Bhilwade, Naoto Tatewaki, Tetsuya Konishi, Miyako Nishida, Takahiro Eitsuka, Hironobu Yasui, Osamu Inanami, Osamu Handa, Yuji Naito, Nobuo Ikekawa, Hiroshi Nishida
The scientific community is pursuing to understand the potential of functional foods and their role in maintaining and optimizing health and reduce risk for a variety of chronic diseases like cancer. Chemoprevention has become an important strategy for reducing cancer risk where in food factors and natural products are attracting much attention to modulate signals related to carcinogenesis (1, 2). Another important approach is to use the adjuvant potential of these compounds along with cancer chemo-therapy and radio-therapy. Natural products with proven safety in human have shown potential for effective inhibition of carcinogenesis (3). In chemotherapy, doxorubicin (DOX) is one of the most commonly used cytotoxic agents for the treatment of a variety of solid malignant tumors. Despite its anticancer activity, the clinical use of DOX is often limited largely because of its severe side effects, including cardiotoxicity and myelosuppression (4).
Assessment of bendamustine-induced genotoxicity in eukaryotic cells
Published in Drug and Chemical Toxicology, 2019
Tais Susane Pereira, Juliane Rocha de Sant’anna, Janicelle Fernandes Morais, Joana Paula Rocha de Sant’anna Yajima, Paulo Cezar de Freitas Mathias, Claudinéia Conationi da Silva Franco, Marialba Avezum Alves de Castro-Prado
The DNA-damaging potential of doxorubicin, a topoisomerase II inhibitor, was previously demonstrated by the induction of micronuclei formation and chromosomal aberrations in cultured human lymphocytes. Doxorubicin induced a statistically significant dose-dependent increase in micronuclei frequency in binucleated cells and a variety of aberrations, including terminal deletions, breaks, exchanges, fragment formation, ends-rejoining, and interstitial deletions (Khan et al. 2009). Doxorubicin is used to treat a variety of systemic cancers and solid tumors, including leukemias, lymphomas, sarcomas, breast cancers, lung cancers, neuroblastoma, and germ-cell malignancies. (Pendleton et al. 2014). In a previous work, the induction of chromosome breaks and sister chromatid exchanges were reported in cancer patients after receiving doxorubicin-containing chemotherapy (Sen et al. 1990).
Related Knowledge Centers
- Chemotherapy
- Cancer
- Breast Cancer
- Bladder Cancer
- Kaposi's Sarcoma
- Lymphoma
- Acute Lymphoblastic Leukemia
- History of Cancer Chemotherapy
- Intravenous Therapy
- Hair Loss